Senzime AB Earnings Call: Growth Paused, Momentum Intact

Senzime AB ((SE:SEZI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Senzime AB’s latest earnings call struck a cautiously upbeat tone, as management highlighted powerful underlying momentum in sensors, recurring revenue and margins despite a soft Q1 in reported growth. Executives framed the quarter as an operationally strong but statistically weak “outlier,” with delayed U.S. deals, FX and tariffs masking progress, while reaffirming confidence in full‑year and 2026 targets.

Sensor Momentum and Recurring Revenue Foundation

Sensor sales climbed about 40% in constant currencies, with rolling 12‑month volumes up roughly 27%, underscoring the shift toward a recurring‑revenue model. The company also crossed the milestone of 1,000,000 monitored patients, reinforcing sensors as the primary revenue driver and key source of gross margin leverage.

U.S. Disposables and TetraGraph‑as‑a‑Service

In the U.S., disposables expanded about 55% in local currency, helping the overall U.S. business grow around 11% in local terms despite headline weakness. Senzime shipped 246 TetraGraphs, with 120 under the TetraGraph‑as‑a‑Service model, where early deals closed in roughly half the time of traditional capital sales and promise higher long‑term sensor margins.

Installed Base Growth and Pediatric Expansion

Cumulative TetraGraph shipments now exceed 5,500 units, confirming a steadily expanding installed base even as Q1 volumes slipped to 376 from 443 a year earlier. Pediatric use emerged as a bright spot, with 65 monitors delivered to pediatric operating rooms and a threefold increase in pediatric sensor units during the quarter.

Margin Progress Behind FX and Tariffs

Underlying gross margin improved to about 69.2%, reflecting better scale and pricing discipline, even though reported margin was only 63.1% after FX and tariff drag. Management reported roughly 5% higher U.S. average selling prices and expects continued margin expansion as volume grows and pricing initiatives gain traction.

Cost Discipline and Strengthened Liquidity

Operating expenses fell around 5% year over year and roughly 17.5% versus Q4, helping narrow losses despite continued investment in growth. Operating cash flow improved by about 33% but stayed negative, while cash of SEK 55.3m plus around SEK 42.5m in undrawn credit gives the company some runway to execute its plan.

Clinical Tailwinds and New Connectivity Platform

New European pediatric guidelines recommending quantitative, preferably EMG‑based, monitoring provide a powerful clinical endorsement for Senzime’s technology. The launch of TetraCom, which enables EHR connectivity with major platforms and monitoring partners, opens new avenues for integration‑driven adoption and potential recurring service revenues.

Big U.S. Wins and a Deepening Pipeline

Senzime secured notable U.S. wins, including Ivy League centers, a large IDN expansion carrying an estimated SEK 6m annual run rate, a Florida hospital extension and a major children’s hospital in Texas. With roughly 250 U.S. hospitals now customers, management emphasized a robust pipeline as a key reason for maintaining its aggressive growth ambitions.

Q1 as an Outlier: Delayed U.S. Deals

Management labeled Q1 a temporary outlier, as slower U.S. monitor deal closings and elongated purchasing cycles drove a roughly 5% decline in reported U.S. sales. Many of these deals were pushed into Q2 rather than lost, suggesting that near‑term execution on closing and implementation will be crucial to restoring growth momentum.

FX and Tariffs Distorting the Headline Numbers

A strong SEK against the USD and significant tariffs weighed on both reported sales and margins, with currency headwinds alone estimated at about SEK 2.5m. The company also paid around SEK 5m in U.S. tariffs, and while potential reimbursement is being pursued, management acknowledged that FX and tariff outcomes remain outside its direct control.

Lower Shipments Versus a Tough Comparator

Quarterly shipments fell to 376 units from 443 units in the prior‑year period, reflecting a decline of roughly 15% that partly stems from last year’s unusually strong upgrades and demo activity. Management framed this as a normalization rather than a structural setback, pointing to cumulative shipments and sensor growth as more relevant indicators.

Asian Regulatory and Timing Frictions

Japan and South Korea were cited as sources of timing and regulatory delays, shifting the cadence of shipments and near‑term sensor volumes in the region. Approval processes, particularly in South Korea, have slowed rollouts, pushing some expected contribution into later periods and adding another execution variable to the growth story.

Cash Flow Still Negative and Execution Risk

Despite meaningful improvement, operating cash flow remains in the red, underscoring that self‑funded growth is still a work in progress. To reach its goal of being cash‑flow positive by Q4 2026, Senzime must deliver sustained sales growth, continued margin expansion, working‑capital efficiencies and potentially recover a portion of the tariff burden.

Sales‑Cycle and Adoption Challenges

The company acknowledged ongoing risks from long hospital purchasing cycles, contracting delays and clinician resistance to changing protocols, particularly across large IDNs. Full penetration will require persistent key‑opinion‑leader support and formal protocolization, meaning the adoption curve may remain uneven even if the clinical case is compelling.

Guidance and Outlook Remain Firm

Senzime reiterated its full‑year 2026 targets and expects sales growth in line with the roughly 60% five‑year CAGR, alongside a goal of being cash‑flow positive by Q4 2026. Management guided to a Q2 rebound and further margin gains on top of the 69.2% underlying gross margin in Q1, while holding operating expenses flat to down from the SEK 35.6m reported this quarter.

Management closed the call emphasizing that Q1’s soft reported growth masks sturdy fundamentals in sensors, recurring revenue and gross margin improvement. If the company can close delayed deals, navigate FX and tariffs and execute on regulatory rollouts, the upbeat tone and reiterated targets suggest meaningful upside potential for investors watching this growth story unfold.